Bevacizumab
Identification
- Summary
Bevacizumab is a monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
- Brand Names
- Avastin, Mvasi
- Generic Name
- Bevacizumab
- DrugBank Accession Number
- DB00112
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.14,6,8,24 VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.5,7,6,8,9
In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market.23,24 It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A.7,14 Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer.25 Bevacizumab was approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021.32,29 There are several biosimilars of bevacizumab, such as bevacizumab-awwb, bevacizumab-maly, bevacizumab-adcd, and bevacizumab-tnjn.
Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI).26 As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19.26
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Structure
- Protein Chemical Formula
- C6538H10034N1716O2033S44
- Protein Average Weight
- 149000.0 Da
- Sequences
>"Bevacizumab light chain" DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>"Bevacizumab heavy chain" EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTY AADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Download FASTA Format- Synonyms
- Anti-VEGF Humanized Monoclonal Antibody
- Anti-VEGF monoclonal antibody
- Bevacizumab
- bevacizumab-awwb
- rhuMAb-VEGF
- External IDs
- ABP 215
- ABP-215
- BI 695502
- GB222
- LY01008
- MIL60
- R-435
Pharmacology
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; fallopian tube cancer; breast cancer; and recurrent glioblastoma.25,27,28,29,30,33
Interestingly, bevacizumab is currently under investigation for the treatment of COVID-19 complications including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).26
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Cervical cancer metastatic Regimen in combination with: Paclitaxel (DB01229), Cisplatin (DB00515) •••••••••••• ••••••••• Used in combination to treat Cervical cancer metastatic Regimen in combination with: Paclitaxel (DB01229), Topotecan (DB01030) •••••••••••• ••••••••• Used in combination to treat Metastatic breast cancer Regimen in combination with: Capecitabine (DB01101) •••••••••••• ••••• •••••••••• •• •• •••••••••• •• ••••• ••••••••• Used in combination to treat Metastatic breast cancer Regimen in combination with: Paclitaxel (DB01229) •••••••••••• ••••• Used in combination to treat Metastatic colorectal cancer (crc) •••••••••••• ••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Bevacizumab binds circulating vascular endothelial-derived growth factor (VEGF) and blocks it from binding to its associated receptors, effectively blunting downstream signaling.19 The effects of bevacizumab have been shown to re-establish normal vasculature at the tumor site resulting in increased nutrient and oxygen supply, while also improving the delivery of chemotherapeutic drugs to the target area.14,18 On the other hand, VEGF signaling is a vital component of several processes including angiogenesis, lymphangiogenesis, blood pressure regulation, wound healing, coagulation, and renal filtration.5,7,19 Although blocking VEGF may inhibit metastatic disease progression, it may also result in unintended effects due to the role of VEGF in several other physiologic processes.25
- Mechanism of action
Transcription of the VEGF protein is induced by 'hypoxia inducible factor' (HIF) in a hypoxic environment.14 When circulating VEGF binds to VEGF receptors (VEGFR-1 and VEGFR-2) located on endothelial cells, various downstream effects are initiated.5,14 It should be noted that VEGF also binds to the neuropilin co-receptors (NRP-1 and NRP-1), leading to enhanced signaling.14,17
Cancer cells promote tumor angiogenesis by releasing VEGF, resulting in the creation of an immature and disorganized vascular network.9,10 The hypoxic microenvironment promoted by cancer cells favors the survival of more aggressive tumor cells, and gives rise to a challenging environment for immune cells to respond appropriately.10,11,12 As a result, VEGF has become a well-known target for anti-cancer drugs like bevacizumab.6 Bevacizumab is a mAb that exerts its effects by binding and inactivating serum VEGF.14 When bound to the mAb, VEGF is unable to interact with its cell surface receptors, and proangiogenic signalling is inhibited.14 This prevents formation of new blood vessels, decreases tumor vasculature, and reduces tumor blood supply.14,25
There is also evidence to suggest that VEGF is upregulated in COVID-19 patients, hence, bevacizumab is being investigated for the treatment of associated complications.26 Higher levels of VEGF may contribute to pulmonary edema, leading to acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).26 Researchers are hopeful that by inhibiting VEGF, bevacizumab may effectively treat ARDS and ALI - both common features of severe COVID-19 cases.26
Target Actions Organism AVascular endothelial growth factor A Not Available Humans UComplement C1q subcomponent subunit A Not Available Humans UComplement C1q subcomponent subunit B Not Available Humans UComplement C1q subcomponent subunit C Not Available Humans ULow affinity immunoglobulin gamma Fc region receptor III-A Not Available Humans UHigh affinity immunoglobulin gamma Fc receptor I Not Available Humans ULow affinity immunoglobulin gamma Fc region receptor II-a Not Available Humans ULow affinity immunoglobulin gamma Fc region receptor II-b Not Available Humans ULow affinity immunoglobulin gamma Fc region receptor II-c Not Available Humans - Absorption
Monoclonal antibodies (mAbs) are large in size, do not readily cross cell membranes, and are unable to withstand proteolysis in the gastrointestinal tract.16,21,22 Given these characteristics, mAbs are poorly absorbed via the oral route and are instead administered intravenously, intramuscularly or subcutaneously.16,22
In a single dose (1mg/kg) pharmacokinetic study assessing the bioequivalence of bevacizumab and TAB008 (a biosimilar product), the pharmacokinetic parameters of Avastin (bevacizumab) were as follows20: Geometric mean Cmax = 17.38 ug/mL Geometric mean AUCinf = 5,358 ugxh/mL Geometric mean Tmax = 2.50 hrs
- Volume of distribution
The volume of distribution of bevacizumab is approximately 3.29 L and 2.39 L for the average male and female, respectively.14
- Protein binding
>97% of serum VEGF is bound to bevacizumab.14
- Metabolism
There are several pathways through which monoclonal antibodies (mAbs) may be cleared.15 Non-specific clearance of mAbs refers to target independent pinocytosis, and proteolysis of the protein into small amino acids and peptides in the reticuloendothelial system (RES) and the liver.15,16 Target-mediated clearance is a result of specific interactions between the mAb and its target antigen.15 Once bound, the antibody-antigen complex may be cleared via lysosomal degradation.15,16 Additionally, the production of anti-drug antibodies (ADA), which are a result of an immunogenic response to mAb-based treatment, can form complexes with mAb’s and may impact the rate of mAb clearance.15
- Route of elimination
Due to their size, monoclonal antibodies are not renally eliminated under normal physiological conditions.16 Catabolism or excretion are the primary processes of elimination.16
- Half-life
The half-life of bevacizumab is estimated to be 20 days (range of 11-50 days).25,13
- Clearance
The clearance (CL) of bevacizumab is approximately 0.207 L/day.14 The CL of bevacizumab can increase or decrease by 30% in patients who weigh >114 kg or <49 kg respectively.14 Males tend to clear bevacizumab at a faster rate than females (26% faster on average).14 Other factors including alkaline phosphatase (ALP), serum aspartate aminotransferase (AST), serum albumin, and tumor burden may cause the CL to fluctuate.14
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Bevacizumab toxicities are distinct from the effects of cytotoxic agents used in chemotherapy, and are normally linked to impaired VEGF function.18,19 Common toxicities associated with bevacizumab include hypertension, gastrointestinal perforation, arterial thromboembolism, reversible posterior leukoencephalopathy syndrome (RPLS), venous thromboembolism, proteinuria, bleeding/hemorrhage, and wound-healing complications.18
- Pathways
Pathway Category Bevacizumab Action Pathway Drug action - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Bevacizumab. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab. Aducanumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Abevmy Injection, solution, concentrate 25 mg/ml Intravenous Mylan Ire Healthcare Limited 2021-10-07 Not applicable EU Abevmy Solution 100 mg / 4 mL Intravenous Biosimilar Collaborations Ireland Limited 2022-04-13 Not applicable Canada Abevmy Injection, solution, concentrate 25 mg/ml Intravenous Mylan Ire Healthcare Limited 2021-10-07 Not applicable EU Abevmy Injection, solution, concentrate 25 mg/ml Intravenous Mylan Ire Healthcare Limited 2021-10-07 Not applicable EU Abevmy Solution 400 mg / 16 mL Intravenous Biosimilar Collaborations Ireland Limited 2022-04-13 Not applicable Canada
Categories
- ATC Codes
- L01FG01 — Bevacizumab
- L01FG — VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
- L01 — ANTINEOPLASTIC AGENTS
- L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Antibodies
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Antineoplastic and Immunomodulating Agents
- Antineovascularisation Agents
- Blood Proteins
- Cancer immunotherapy
- Cardiotoxic antineoplastic agents
- Experimental Unapproved Treatments for COVID-19
- Globulins
- Growth Inhibitors
- Immunoglobulins
- Immunoproteins
- Immunotherapy
- MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
- Narrow Therapeutic Index Drugs
- Ocular Vascular Disorder Agents
- Ophthalmologicals
- Proteins
- Sensory Organs
- Serum Globulins
- Vascular Endothelial Growth Factor Inhibitor
- Vascular Endothelial Growth Factor Inhibitors
- Vascular Endothelial Growth Factor-directed Antibody Interactions
- VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 2S9ZZM9Q9V
- CAS number
- 216974-75-3
References
- General References
- Velcheti V, Viswanathan A, Govindan R: The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey. J Thorac Oncol. 2006 Jun;1(5):501. [Article]
- Rosen LS, Jacobs IA, Burkes RL: Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol. 2017 Oct;12(5):599-610. doi: 10.1007/s11523-017-0518-1. [Article]
- Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, Allison DE, Jin J: Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016 Aug;78(2):341-51. doi: 10.1007/s00280-016-3079-6. Epub 2016 Jun 21. [Article]
- Apsangikar PD, Chaudhry SR, Naik MM, Deoghare SB, Joseph J: Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. Indian J Cancer. 2017 Jul-Sep;54(3):535-538. doi: 10.4103/ijc.IJC_394_17. [Article]
- Karaman S, Leppanen VM, Alitalo K: Vascular endothelial growth factor signaling in development and disease. Development. 2018 Jul 20;145(14). pii: 145/14/dev151019. doi: 10.1242/dev.151019. [Article]
- Verheul HM, Pinedo HM: The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S80-4. doi: 10.3816/cbc.2000.s.015. [Article]
- Stacker SA, Achen MG: The VEGF signaling pathway in cancer: the road ahead. Chin J Cancer. 2013 Jun;32(6):297-302. doi: 10.5732/cjc.012.10319. Epub 2013 Feb 19. [Article]
- Siveen KS, Prabhu K, Krishnankutty R, Kuttikrishnan S, Tsakou M, Alali FQ, Dermime S, Mohammad RM, Uddin S: Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges. Curr Vasc Pharmacol. 2017;15(4):339-351. doi: 10.2174/1570161115666170105124038. [Article]
- Lee SH, Jeong D, Han YS, Baek MJ: Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015 Jul;89(1):1-8. doi: 10.4174/astr.2015.89.1.1. Epub 2015 Jun 11. [Article]
- Viallard C, Larrivee B: Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017 Nov;20(4):409-426. doi: 10.1007/s10456-017-9562-9. Epub 2017 Jun 28. [Article]
- Rodriguez PC, Zea AH, Ochoa AC: Mechanisms of tumor evasion from the immune response. Cancer Chemother Biol Response Modif. 2003;21:351-64. doi: 10.1016/s0921-4410(03)21018-8. [Article]
- Petrova V, Annicchiarico-Petruzzelli M, Melino G, Amelio I: The hypoxic tumour microenvironment. Oncogenesis. 2018 Jan 24;7(1):10. doi: 10.1038/s41389-017-0011-9. [Article]
- Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J: Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86. doi: 10.1007/s00280-007-0664-8. Epub 2008 Jan 19. [Article]
- Kazazi-Hyseni F, Beijnen JH, Schellens JH: Bevacizumab. Oncologist. 2010;15(8):819-25. doi: 10.1634/theoncologist.2009-0317. Epub 2010 Aug 5. [Article]
- Ovacik M, Lin K: Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clin Transl Sci. 2018 Nov;11(6):540-552. doi: 10.1111/cts.12567. Epub 2018 Aug 7. [Article]
- Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29. [Article]
- Herzog B, Pellet-Many C, Britton G, Hartzoulakis B, Zachary IC: VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Mol Biol Cell. 2011 Aug 1;22(15):2766-76. doi: 10.1091/mbc.E09-12-1061. Epub 2011 Jun 8. [Article]
- Randall LM, Monk BJ: Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010 Jun;117(3):497-504. doi: 10.1016/j.ygyno.2010.02.021. Epub 2010 Apr 2. [Article]
- Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E: Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist. 2015 Feb;20(2):166-75. doi: 10.1634/theoncologist.2014-0330. Epub 2015 Jan 7. [Article]
- Wang J, Qi L, Liu L, Wang Z, Chen G, Wang Y, Liu X, Liu Y, Liu H, Tong Y, Liu C, Lei C, Wang X: A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers. Front Pharmacol. 2019 Aug 15;10:905. doi: 10.3389/fphar.2019.00905. eCollection 2019. [Article]
- Yang NJ, Hinner MJ: Getting across the cell membrane: an overview for small molecules, peptides, and proteins. Methods Mol Biol. 2015;1266:29-53. doi: 10.1007/978-1-4939-2272-7_3. [Article]
- Keizer RJ, Huitema AD, Schellens JH, Beijnen JH: Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010 Aug;49(8):493-507. doi: 10.2165/11531280-000000000-00000. [Article]
- Goodman L: Persistence--luck--Avastin. J Clin Invest. 2004 Apr;113(7):934. doi: 10.1172/JCI21507. [Article]
- Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR: Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012 Dec;32(12):1095-111. doi: 10.1002/phar.1147. [Article]
- FDA Approved Drug Products: AVASTIN (bevacizumab) injection, for intravenous use [Link]
- ClinicalTrials.gov: Bevacizumab in Severe or Critical Patients with COVID-19 Pneumonia (BEST-CP) [Link]
- FDA Approved Drug Products: MVASI (bevacizumab-awwb) injection, for intravenous use [Link]
- FDA Approved Drug Products: ALYMSYS (bevacizumab-maly) injection, for intravenous use [Link]
- EMA Approved Drug Products: Abevmy (bevacizumab) Intravenous Infusion [Link]
- FDA Approved Drug Products: VEGZELMA (bevacizumab-adcd) injection, for intravenous use [Link]
- Health Canada Approved Drug Product: VEGZELMA (bevacizumab) injection, for intravenous use [Link]
- Health Canada approves AVASTIN(R) for treatment of most aggressive form of brain cancer [Link]
- FDA Approved Drug Products: Avzivi (bevacizumab-tnjn) injection, for intravenous use [Link]
- External Links
- PubChem Substance
- 46504473
- 253337
- ChEMBL
- CHEMBL1201583
- Therapeutic Targets Database
- DAP000393
- PharmGKB
- PA130232992
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Bevacizumab
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Abdominal wall neoplasm / Fallopian Tube Neoplasms / Ovarian Neoplasms 1 4 Active Not Recruiting Treatment Ovarian Cancer 1 4 Completed Not Available Diabetic Macular Edema (DME) / Diabetic Retinopathy (DR) 1 4 Completed Health Services Research Age - Related Macular Degeneration (AMD) 1 4 Completed Other Eye Diseases / Premature Births / Retinal Diseases / Retinopathy of Prematurity Both Eyes 1
Pharmacoeconomics
- Manufacturers
- Roche Pharmaceuticals
- Packagers
- F Hoffmann-La Roche Ltd.
- Genentech Inc.
- Dosage Forms
Form Route Strength Solution, concentrate Intravenous 2500000 mg Solution Intravenous 100 mg/4ml Solution Intravenous 400 mg/16ml Injection Intravenous Injection, solution, concentrate Intravenous; Parenteral 100 mg/4ml Injection, solution, concentrate Intravenous; Parenteral 400 mg/16ml Solution Intravenous 25 mg / mL Solution Intravenous 400.000 mg Solution Intravenous 25 mg Injection Intravenous 25 MG/ML Solution, concentrate Intravenous 400 mg Solution, concentrate Intravenous 100 mg Injection, solution, concentrate Intravenous 25 MG/ML Injection, solution, concentrate Intravenous 25 mg/1ml Injection, solution Intravenous 25 mg/mL Injection, solution Intravenous 100 mg/4mL Injection, solution Intravenous 400 mg/16mL Injection, solution, concentrate Intravenous; Parenteral 25 MG/ML Solution Intravenous 100.00 mg Injection, solution, concentrate 100 mg/4ml Injection, solution, concentrate 400 mg/16ml Injection, solution Intravenous Solution Intravenous 25 mg/mL Injection, solution, concentrate Intravenous 100 mg/4ml Injection, solution, concentrate Intravenous 400 mg/16ml Solution Intravenous 100 mg / 4 mL Solution Intravenous 400 mg / 16 mL Injection Intravenous 100 mg/4ml Injection Intravenous 400 mg/16ml Solution Intravenous 100 mg Solution Intravenous 400 mg Solution, concentrate Intravenous 25 mg Solution Intravenous 25 mg/1ml - Prices
Unit description Cost Unit Avastin 400 mg/16ml Solution 16ml Vial 2786.78USD vial Avastin 100 mg/4ml Solution 4ml Vial 696.7USD vial Avastin 100 mg/4 ml vial 167.48USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA2286330 No 2008-06-10 2018-04-03 Canada CA2145985 No 2003-09-16 2012-10-28 Canada
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 61 °C (FAB fragment), 71 °C (whole mAb) Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
Targets
![](https://go.drugbank.com/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png)
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- General Function
- Vascular endothelial growth factor receptor binding
- Specific Function
- Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
- Gene Name
- VEGFA
- Uniprot ID
- P15692
- Uniprot Name
- Vascular endothelial growth factor A
- Molecular Weight
- 27042.205 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Gerber HP, Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005 Feb 1;65(3):671-80. [Article]
- Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, Allison DE, Jin J: Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016 Aug;78(2):341-51. doi: 10.1007/s00280-016-3079-6. Epub 2016 Jun 21. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proe...
- Gene Name
- C1QA
- Uniprot ID
- P02745
- Uniprot Name
- Complement C1q subcomponent subunit A
- Molecular Weight
- 26016.47 Da
References
- Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proe...
- Gene Name
- C1QB
- Uniprot ID
- P02746
- Uniprot Name
- Complement C1q subcomponent subunit B
- Molecular Weight
- 26721.62 Da
References
- Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proe...
- Gene Name
- C1QC
- Uniprot ID
- P02747
- Uniprot Name
- Complement C1q subcomponent subunit C
- Molecular Weight
- 25773.56 Da
References
- Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as...
- Gene Name
- FCGR3A
- Uniprot ID
- P08637
- Uniprot Name
- Low affinity immunoglobulin gamma Fc region receptor III-A
- Molecular Weight
- 29088.895 Da
References
- Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Receptor signaling protein activity
- Specific Function
- High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.
- Gene Name
- FCGR1A
- Uniprot ID
- P12314
- Uniprot Name
- High affinity immunoglobulin gamma Fc receptor I
- Molecular Weight
- 42631.525 Da
References
- Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized ...
- Gene Name
- FCGR2A
- Uniprot ID
- P12318
- Uniprot Name
- Low affinity immunoglobulin gamma Fc region receptor II-a
- Molecular Weight
- 35000.42 Da
References
- Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complex...
- Gene Name
- FCGR2B
- Uniprot ID
- P31994
- Uniprot Name
- Low affinity immunoglobulin gamma Fc region receptor II-b
- Molecular Weight
- 34043.355 Da
References
- Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transmembrane signaling receptor activity
- Specific Function
- Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulat...
- Gene Name
- FCGR2C
- Uniprot ID
- P31995
- Uniprot Name
- Low affinity immunoglobulin gamma Fc region receptor II-c
- Molecular Weight
- 35577.96 Da
References
- Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9. [Article]
Drug created at June 13, 2005 13:24 / Updated at January 31, 2024 01:10